在情况较差的病人组中，所有组的五年无病生存率以及估测十年总生存率在每个时间段内均相差不多，在84%到88%之间。
In the group with unfavorable features, 5-year event-free survival and estimates of 10-year overall survival were similar in all treatment groups and for each time period, ranging from 84% to 88%.
无论如何，除了90年代初期十分高龄的患者总的生存率还是都有所提高。
However, survival has improved in all but the very oldest ages since the early 1990s.
二级终点包含了目标反应率，一年生存期，总生存率，化疗类型和安全性PFS评估。
Secondary endpoints included objective response rate, one-year survival rate, overall survival, PFS assessment by chemotherapy type and safety.
两组患者的5年总的生存率都接近70%以及无复发的生存率大约为62%。
In both groups, overall 5-year survival rate was approximately 70% and recurrence-free survival rate was about 62%.
在确诊时的转化预示相对较好的预后，5年无进展生存率和总生存率分别达到66%和88%。
Transformation at the time of diagnosis portends a more favorable prognosis with 5-year PFS and OS rates of 66% and 88%, respectively.
10年累计发生组织学转变的累计风险为22%（95%CI 15-29），在发生转化后3年的总生存率是71%（95% CI58-87%）。
The 10-year cumulative risk of histological transformation was 22% (95%CI 15-29) and the 3-year OS after transformation was 71% (95%CI 58-87%).
10年累计发生组织学转变的累计风险为22%（95%CI 15-29），在发生转化后3年的总生存率是71%（95% CI58-87%）。
The 10-year cumulative risk of histological transformation was 22% (95%CI 15-29) and the 3-year OS after transformation was 71% (95%CI 58-87%).
应用推荐